Drug intelligence / Profile preview

APX-343A

Development stage: Phase 1
Lead developer: Aptabio Therapeutics
Modality: Small Molecules, Vaccines & Immunotherapeutics
Administration: Oral

Overview

APX-343A is an investigational anticancer immunotherapy drug developed by AptaBio Therapeutics. It targets cancer-associated fibroblasts (CAFs) within the tumor microenvironment and is designed to modulate oxidative stress, thereby regulating CAFs to enhance antitumor immune responses and inhibit tumor development and metastasis. This novel mechanism aims to overcome challenges such as low response rates and resistance seen with current immunotherapies. APX-343A is classified as a new molecular entity and is currently in Phase I clinical trials for the treatment of solid tumors[1][2][3][4].

Targets

NOX4 (NADPH oxidase 4)NOX2 (NADPH oxidase 2)

Beyond the preview

Go deeper on APX-343A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on APX-343A.

Explore the full profile